[Ca 2ϩ ]i and myofilament Ca 2ϩ sensitivity in the pulmonary venous smooth muscle (PVSM) contractile response to the thromboxane A2 mimetic U-46619 and to assess the roles of PKC, tyrosine kinases (TK), and Rho-kinase (ROK) in that response. We tested the hypothesis that U-46619-induced contraction in PVSM is mediated by both increases in [Ca 2ϩ ]i and myofilament Ca 2ϩ sensitivity and that the PKC, TK, and ROK signaling pathways are involved. Isometric tension was measured in isolated endothelium-denuded (EϪ) canine pulmonary venous (PV) rings. In addition, [Ca 2ϩ ]i and tension were simultaneously measured in fura-2-loaded EϪ PVSM strips. U-46619 (0.1 nM-1 M) caused dose-dependent (P Ͻ 0.001) contraction in PV rings. U-46619 contraction was attenuated by inhibitors of L-type voltage-operated Ca 2ϩ channels (nifedipine, P Ͻ 0.001), inositol 1,4,5-trisphosphate-mediated Ca 2ϩ release (2-aminoethoxydiphenylborate, P Ͻ 0.001), PKC (bisindolylmaleimide I, P Ͻ 0.001), TK (tyrphostin A-47, P ϭ 0.014), and ROK (Y-27632, P ϭ 0.008). In PV strips, U-46619 contraction was associated with increases in [Ca 2ϩ ]i and myofilament Ca 2ϩ sensitivity. Both Ca 2ϩ influx and release mediated the early transient increase in [Ca 2ϩ ]i, whereas the late sustained increase in [Ca 2ϩ ]i only involved Ca 2ϩ influx. Inhibition of both PKC and ROK (P ϭ 0.006 and P ϭ 0.002, respectively), but not TK, attenuated the U-46619-induced increase in myofilament Ca 2ϩ sensitivity. These results suggest that U-46619 contraction is mediated by Ca 2ϩ influx, Ca 2ϩ release, and increased myofilament Ca 2ϩ sensitivity. The PKC, TK, and ROK signaling pathways are involved in U-46619 contraction. pulmonary vein; Ca 2ϩ homeostasis; myofilament Ca 2ϩ sensitivity THROMBOXANE A 2 (TXA 2 ) is a major product of arachidonic acid metabolism via the cyclooxygenase pathway. TXA 2 is a potent stimulator of platelet aggregation and smooth muscle contraction and may play a role as a mediator of myocardial infarction, atherosclerosis, and bronchial asthma (22). Increased activity of TXA 2 has also been implicated in several forms of human and experimental pulmonary hypertension, including pulmonary hypertension induced by sepsis (36), heparin/protamine (19), and ischemia-reperfusion (39).The TXA 2 analog, U-46619, is known to cause constriction of pulmonary veins (13). Pulmonary venous constriction can increase pulmonary capillary pressure and transvascular fluid flux to cause pulmonary edema, which can adversely affect blood oxygenation and right ventricular function. Agonistinduced vascular smooth muscle contraction is mediated by an increase in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) and/or an increase in myofilament Ca 2ϩ sensitivity. We are aware of only one study that has investigated the effects of TXA 2 on [Ca 2ϩ ] i in pulmonary veins (13). In that study, changes in tension in response to the TXA 2 analog, U-46619, were measured in pulmonary venous rings, whereas changes in [Ca 2ϩ ] i were measured separately in dispersed pulmonary venous smo...